logo
  

Merck: Phase 3 KEYNOTE-859 Trial Meets Primary Endpoint Of Overall Survival

Merck (MRK) reported positive topline results from the Phase 3 KEYNOTE-859 trial investigating KEYTRUDA in combination with chemotherapy for the first-line treatment of patients with human epidermal growth factor receptor 2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. In the trial, KEYTRUDA in combination with chemotherapy showed a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival versus chemotherapy alone in the all-randomized patient population at a pre-specified interim analysis conducted by an independent Data Monitoring Committee. Statistically significant and clinically meaningful improvements in progression-free survival and overall response rate were also observed. The safety profile was consistent with that observed in previously reported studies.

"The results from KEYNOTE-859 show the potential of KEYTRUDA plus chemotherapy to improve survival beyond chemotherapy alone for patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression," said Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Salt Lake City, Utah-based Rocky Mountain Pies, LLC is recalling Red Button Vintage Creamery French Silk Pie citing possible presence of undeclared almonds, a known allergen, the U.S. Food and Drug Administration said. The recall involves 31.88 oz French Silk Pie with the lot code beginning with 2 266. Only UPC code 0 41172 81290 9 is involved in the recall. The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert against Paradise Locker Meats' certain fully cooked summer sausage products. There are concerns that the products may be contaminated with extraneous materials, specifically plastic. A recall was not requested as the products are no longer available for purchase. Hormel Foods Corp. (HRL) said, in the fourth quarter, the company delivered earnings per share comparable with record results last year, which included an additional week of sales. Pretax earnings were $357 million, up 1% from a year ago. Organic net sales were up 2%, excluding the impact of an additional...
Follow RTT